Filing Analysis
Cerenome, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2026. The filing serves as a formal announcement of quarterly earnings and recent corporate updates.
📋 Key Facts
- Reported financial results for the first quarter ended March 31, 2026.
- Filed on August 14, 2026.
- The filing includes a press release as Exhibit 99.1 regarding recent corporate updates.
Cerenome, Inc. (formerly Plus Therapeutics, Inc.) has officially changed its corporate name and trading symbol on the Nasdaq Capital Market. The change is effective as of August 3, 2026.
📋 Key Facts
- Corporate name changed from 'Plus Therapeutics, Inc.' to 'Cerenome, Inc.' effective August 3, 2026.
- Trading symbol changed from 'PSTV' to 'CNSY' on the Nasdaq Capital Market.
- The CUSIP number remains unchanged despite the name and symbol change.
- Amendment filed with the Secretary of State of Delaware on July 30, 2026.
Plus Therapeutics entered into an Equity Distribution Agreement with Canaccord Genuity LLC to sell up to $17.35 million of common stock via an 'at-the-market' (ATM) offering. The proceeds are intended for general corporate purposes and working capital.
🚩 Red Flags
- Potential for significant shareholder dilution given the $17.35M cap relative to typical micro-cap market caps
- Use of proceeds is vague ('general corporate purposes and working capital'), which often indicates a need for immediate liquidity
📋 Key Facts
- Agreement date: June 1, 2026
- Maximum aggregate offering price: $17,350,000
- Agent: Canaccord Genuity LLC
- Agent commission: 3.0% of gross proceeds
- Fixed expenses: $75,000 reimbursement for agent's out-of-pocket expenses
- Offering method: 'At the market' (ATM) via Nasdaq Capital Market
- Registration: Pursuant to Form S-3 filed June 2, 2026
Plus Therapeutics reported the results of its 2026 Annual Meeting of Stockholders held on May 14, 2026. Shareholders elected six directors, ratified the company's auditor, and approved an amendment to the 2020 Stock Incentive Plan, while the company noted a recent 1-for-25 reverse stock split.
🚩 Red Flags
- Recent 1-for-25 reverse stock split (effective April 2, 2026), typically used to maintain exchange listing requirements.
- Significant opposition to the Stock Incentive Plan amendment, with approximately 41% of cast votes (excluding abstentions and broker non-votes) voting against the proposal.
- High volume of broker non-votes (50,807,018) relative to the total quorum, indicating a high proportion of shares held in 'street name' that did not provide voting instructions on non-routine matters.
📋 Key Facts
- The Annual Meeting was held on May 14, 2026, with a quorum of 64,857,321 shares represented.
- A 1-for-25 reverse stock split was effective on April 2, 2026; share counts in the filing are presented on a pre-split basis.
- Stockholders approved the Sixth Amendment and Restatement of the 2020 Stock Incentive Plan (7,976,002 votes for vs. 5,648,887 against).
- CBIZ CPAs, P.C. was ratified as the independent auditor for the 2026 fiscal year.
- Six directors were elected to serve until the 2027 Annual Meeting: Howard Clowes, An van Es-Johansson, Richard J. Hawkins, Marc H. Hedrick, Ronald A. Andrews, and Kyle Guse.
Plus Therapeutics, Inc. reported its financial results for the first quarter ended March 31, 2026, and provided corporate updates. The filing serves as a formal disclosure of the company's quarterly performance via a furnished press release.
📋 Key Facts
- Reported financial results for the first quarter ended March 31, 2026.
- The filing was made under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the financial results and corporate updates was furnished as Exhibit 99.1.
- The report was signed by President and CEO Marc H. Hedrick, M.D.
Plus Therapeutics, Inc. has regained compliance with Nasdaq's minimum bid price requirement following a significant 1-for-25 reverse stock split. The company received official notification from Nasdaq on April 20, 2026, confirming it met the requirements of Listing Rule 5550(a)(2).
🚩 Red Flags
- Implementation of a massive 1-for-25 reverse stock split to maintain listing.
- History of non-compliance with Nasdaq minimum bid price requirements.
📋 Key Facts
- Received Nasdaq Notification Letter on April 20, 2026, confirming compliance.
- The company regained compliance with the $1.00 minimum bid price requirement.
- Compliance was achieved through a 1-for-25 reverse stock split effective April 2, 2026.
- The company continues to be listed on The Nasdaq Capital Market under the symbol PSTV.
Plus Therapeutics, Inc. has appointed Dr. Eric J. Daniels as Chief Development Officer, effective April 20, 2026. Dr. Daniels, who previously served as CDO of Kiora Pharmaceuticals, will be responsible for the development and regulatory approval of the company’s pharmaceutical pipeline.
📋 Key Facts
- Dr. Eric J. Daniels appointed as Chief Development Officer effective April 20, 2026.
- Initial annual base salary set at $460,000 with a 40% annual target bonus.
- Inducement equity grant includes 20,000 stock options and 20,000 restricted stock units (RSUs).
- Dr. Daniels previously held leadership roles at Kiora Pharmaceuticals (NASDAQ: KPRX), Bayon Therapeutics, and OccuRx Pty Ltd.
- Severance package includes 12 months of base salary, target bonus, and 9 months of accelerated equity vesting in the event of involuntary termination.
Plus Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its lead drug candidate, REYOBIQ™ (rhenium Re186 obisbemeda), for the treatment of pediatric malignant gliomas.
📋 Key Facts
- The FDA granted Orphan Drug Designation (ODD) on April 8, 2026.
- The designation is for REYOBIQ™ (rhenium Re186 obisbemeda) specifically for pediatric malignant gliomas.
- The filing includes a press release (Exhibit 99.1) detailing the regulatory milestone.
- Plus Therapeutics is headquartered in Houston, Texas, and trades on the Nasdaq Capital Market under the symbol PSTV.
Plus Therapeutics, Inc. implemented a 1-for-25 reverse stock split effective April 2, 2026, to consolidate its share count from approximately 171.6 million to 6.9 million shares. The split did not reduce the number of authorized shares, significantly increasing the company's capacity for future equity issuance and potential dilution.
🚩 Red Flags
- Reverse stock split (1-for-25) is a significant consolidation often used to artificially inflate share price for exchange compliance.
- Authorized shares were not reduced in proportion to the split, creating a massive potential for future shareholder dilution.
📋 Key Facts
- Reverse stock split ratio of 1-for-25 effective as of 12:01 a.m. on April 2, 2026.
- Common stock outstanding reduced from approximately 171,550,698 shares to approximately 6,862,027 shares.
- The number of authorized shares of common stock was not reduced, increasing the pool of shares available for future issuance.
- New CUSIP number for the common stock is 72941H806.
- Fractional shares will be compensated via cash payments based on fair market value.
Plus Therapeutics announced the appointment of Ronald A. Andrews to its Board of Directors, effective March 20, 2026, filling a vacancy created by the resignation of Dr. Robert Lenk. Mr. Andrews is an industry veteran with over 35 years of experience in diagnostics and molecular diagnostics, including leadership roles at Thermo Fisher Scientific and Oncocyte Inc.
📋 Key Facts
- Ronald A. Andrews appointed to the Board and Nominating and Corporate Governance Committee on March 20, 2026.
- Dr. Robert Lenk resigned from the Board on March 20, 2026, with no reported disagreements regarding company operations.
- Mr. Andrews previously served as President and CEO of Oncocyte Inc. (NASDAQ: OCX) and President of the Genetic Sciences Division at Thermo Fisher Scientific (NASDAQ: TMO).
- Mr. Andrews is determined to be an 'independent director' under Nasdaq listing standards.
Plus Therapeutics, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on May 14, 2026. Due to the meeting being scheduled more than 30 days from the anniversary of the prior year's meeting, the company has established new deadlines for shareholder proposals and director nominations.
📋 Key Facts
- The 2026 Annual Meeting of Stockholders is scheduled for May 14, 2026, at 9:00 a.m. ET.
- The record date for stockholders entitled to vote is March 18, 2026.
- The deadline for submitting stockholder proposals under Rule 14a-8 is March 22, 2026.
- The deadline for director nominations or other business under the Company's Bylaws is March 22, 2026, at 5:00 p.m. ET.
- The meeting will be conducted in a virtual-only format.
Plus Therapeutics, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025. The filing serves as a formal vehicle to furnish the earnings press release and provide recent corporate updates.
📋 Key Facts
- Financial results reported for Q4 and fiscal year ended December 31, 2025
- Filing date and earliest event date of March 12, 2026
- Information furnished under Item 2.02 (Results of Operations and Financial Condition)
- Included Exhibit 99.1: Press Release Announcing Financial Results
Plus Therapeutics, Inc. filed this 8-K to disclose the determination of discretionary cash bonuses for its Named Executive Officers (NEOs) for Fiscal Year 2025. The filing provides an updated Summary Compensation Table as required by Item 5.02(f).
🚩 Red Flags
- Significant increase in CEO total compensation from $1.26M in 2024 to $5.57M in 2025, primarily driven by large equity awards ($3.5M in options and $1.1M in RSAs).
📋 Key Facts
- The Compensation Committee approved discretionary cash bonuses for NEOs for Fiscal Year 2025 on February 9, 2026.
- CEO Marc H. Hedrick received total compensation of $5,566,732 in 2025, including $3,531,841 in option awards and $1,100,647 in restricted stock awards.
- CFO Andrew Sims received total compensation of $1,631,279 in 2025.
- The filing updates the Summary Compensation Table previously filed in a Registration Statement on Form S-1.
Plus Therapeutics, Inc. has filed an 8-K to update its corporate presentation for use in meetings with investors and analysts.
📋 Key Facts
- The company updated its investor presentation on January 22, 2026.
- The filing includes Exhibit 99.1 containing the updated slides.
Plus Therapeutics, Inc. completed a significant public offering of common stock and warrants at a combined price of $0.38 per unit, raising approximately $13.3 million in net proceeds. The offering includes substantial dilution through the issuance of nearly 45 million new shares and warrants.
🚩 Red Flags
- Significant dilution: The issuance of ~45 million new shares/warrants at a low price point ($0.38) will heavily dilute existing shareholders.
- Low share price: The offering price of $0.38 is extremely low, often characteristic of distressed micro-cap financing.
- Variable rate transaction prohibition: The underwriting agreement includes strict prohibitions on future 'variable rate transactions' or ATM offerings for 120 days, indicating a highly structured and restrictive capital raise.
📋 Key Facts
- Offered 39,473,684 shares of common stock and an equal number of warrants at a combined price of $0.38 per share/warrant.
- Underwriter (Lake Street Capital Markets, LLC) exercised an over-allotment option for an additional 5,921,052 units on January 14, 2026.
- Net proceeds from the offering totaled approximately $13.3 million after expenses.
- Warrants are immediately exercisable at $0.38 per share and expire in five years.
- The company is subject to a 45-day lock-up period for directors and executive officers regarding existing holdings.
Plus Therapeutics, Inc. has received an additional 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement. The company is currently facing delisting risk and has indicated it may implement a reverse stock split to maintain its listing.
🚩 Red Flags
- Delisting risk: Failure to meet minimum bid price requirements puts the company at risk of being removed from Nasdaq.
- Reverse stock split potential: The company has already signaled it may use a reverse split, which is often viewed negatively by micro-cap investors as a sign of distress.
- Persistent non-compliance: This is a second extension following an initial failure to meet the requirement.
📋 Key Facts
- Received an additional 180-day extension from Nasdaq Staff on November 13, 2025.
- The new deadline to demonstrate compliance with the $1.00 minimum bid price requirement is May 11, 2026.
- The company previously failed to meet the requirement by the original deadline of November 12, 2025.
- Management explicitly stated they will implement a reverse stock split if necessary to regain compliance.
Plus Therapeutics, Inc. has filed an 8-K to report its financial results for the third quarter ended September 30, 2025. The filing serves as a formal announcement of quarterly earnings and recent corporate updates.
📋 Key Facts
- Reported financial results for the third quarter ended September 30, 2025.
- Filing date: October 30, 2025.
- The report includes a press release (Exhibit 99.1) containing detailed financial and corporate updates.
Plus Therapeutics, Inc. entered into a 120-month lease agreement for approximately 11,370 square feet of office space in Houston, Texas. The lease is scheduled to commence on November 1, 2026.
🚩 Red Flags
- Significant long-term lease obligation ($58k+ monthly) for a micro-cap company.
- The lease term is quite long (10 years), creating significant fixed operating expenses through 2036.
📋 Key Facts
- Lease signed with LG 1 Property Owner LP on October 16, 2025.
- Premises located at 6420 Levit Green Boulevard, Houston, Texas 77021.
- Monthly base rent is $58,745, subject to an annual increase of approximately 3%.
- Lease term is 120 calendar months (10 years).
- Commencement date: On or about November 1, 2026.
Plus Therapeutics received notice from Nasdaq confirming compliance with the Market Value of Listing Securities (MVLS) and Equity Standards. This compliance extends the grace period for the company to remedy its $1.00 bid price deficiency until November 12, 2025.
🚩 Red Flags
- Ongoing bid price deficiency (must resolve by Nov 12, 2025).
- One-year Nasdaq monitoring period regarding equity standards; failure to maintain equity could lead to immediate delisting without a cure period.
- Potential for future reverse stock split mentioned in forward-looking statements.
📋 Key Facts
- Company is now in compliance with Nasdaq Listing Rule 5550(b)(2) (MVLS Standard).
- Company is in compliance with the alternative stockholders’ equity threshold under 5550(b)(1).
- The deadline to remedy the $1.00 bid price deficiency has been extended from September 8, 2025, to November 12, 2025.
- The company is subject to a one-year panel monitoring period for the Equity Standard through August 22, 2026.
Plus Therapeutics is working to resolve a delisting determination from Nasdaq regarding non-compliance with the $2.5 million stockholders' equity rule. The company has recently improved its equity position through share sales under an ELOC and is also attempting to meet compliance via the Alternative Market Value of Listed Securities (MVLS) requirement.
🚩 Red Flags
- Delisting determination issued by Nasdaq Staff.
- Reliance on an Equity Line of Credit (ELOC) for capital, which often leads to significant shareholder dilution.
- History of non-compliance with minimum stockholders' equity requirements.
📋 Key Facts
- Nasdaq issued a delisting determination on June 3, 2025, for failing to maintain $2.5 million in stockholders' equity as of March 31, 2025.
- The company requested and was granted an extension by the Nasdaq Hearings Panel on July 22, 2025.
- As of June 30, 2025, stockholders' equity stood at $3 million, satisfying the Equity Rule.
- Since June 30, 2025, the company has sold over $2 million in common stock via a $50 million Equity Line of Credit (ELOC) with Lincoln Park Capital Fund, LLC.
- Shareholders approved the ELOC issuance on August 7, 2025.
- As of August 13, 2025, the company reported an MVLS of at least $35 million for 20 consecutive business days, seeking compliance under Nasdaq Rule 5550(b)(2).
- The company is currently awaiting formal confirmation from Nasdaq regarding compliance with both the Equity Rule and the Alternative MVLS Requirement.
Plus Therapeutics, Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2025. The filing serves as a formal announcement of quarterly earnings and recent corporate updates.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2025.
- Filing date: August 14, 2025.
- The report includes financial results and other recent corporate updates via a press release (Exhibit 99.1).
Plus Therapeutics, Inc. is facing imminent delisting from Nasdaq due to a significant stockholders' equity deficit of ($23.6 million). While a Hearings Panel granted a temporary reprieve, the company must meet strict compliance deadlines regarding equity levels and stock price by mid-August and early September 2025.
🚩 Red Flags
- Significant stockholders' equity deficit of ($23.6 million).
- Imminent deadline (August 14, 2025) to disclose transactions used to achieve equity compliance.
- Requirement to meet a $1.00 minimum bid price requirement by September 8, 2025.
📋 Key Facts
- Company reported a stockholders' equity deficit of ($23,641,000) as of March 31, 2025.
- Nasdaq notified the company on June 3, 2025, of non-compliance with Rule 5550(b)(1) (Minimum Stockholders' Equity Requirement).
- A Hearings Panel decision on July 22, 2025, granted continued listing subject to specific conditions.
- Compliance Condition 1: Must demonstrate compliance with the Minimum Stockholders' Equity Requirement by August 14, 2025 (tomorrow relative to filing date).
- Compliance Condition 2: Must maintain a closing bid price of at least $1.00 for 10 consecutive business days on or before September 8, 2025.
Plus Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders on August 7, 2025, where shareholders approved several key proposals, including a significant reverse stock split and an equity issuance authorization.
🚩 Red Flags
- Approval of a reverse stock split (range up to 1-for-250) is often used to maintain Nasdaq listing compliance due to low share price.
- Authorization for $50M in equity issuance via Lincoln Park Capital Fund, LLC suggests significant potential dilution and reliance on 'at-the-market' style financing.
📋 Key Facts
- Annual Meeting held on August 7, 2025; results certified by inspector of elections.
- Shareholders approved the election of six directors to the Board.
- Approved Nasdaq Listing Rule 5635(d) compliance: authorization to issue up to $50M in common stock and $1M in commitment fees to Lincoln Park Capital Fund, LLC.
- Approved a reverse stock split with a ratio range between 1-for-2 and 1-for-250, to be implemented within 12 months if the Board chooses.
- Approved advisory vote on executive compensation and an amendment to the 2020 Stock Incentive Plan.
- Quorum was met by 29,973,272 shares (approx. 49.6% of outstanding shares) represented in person or by proxy.
Plus Therapeutics, Inc. has dismissed its independent auditor, BDO USA, P.C., and engaged CBIZ CPAs P.C. as its new independent registered public accounting firm effective July 16, 2025.
🚩 Red Flags
- Dismissal of auditor (Item 4.01) often signals potential friction or disagreements.
- Existing 'going concern' language in previous audit reports for FY2023 and FY2024.
- History of material weakness in internal controls over financial reporting regarding grant revenue.
📋 Key Facts
- BDO USA, P.C. was dismissed by the Audit Committee on July 16, 2025.
- CBIZ CPAs P.C. has been engaged to audit consolidated financial statements for the year ending December 31, 2025.
- Previous audit reports (FY2023 and FY2024) included an explanatory paragraph regarding substantial doubt about the Company's ability to continue as a going concern.
- A material weakness in internal control over financial reporting was disclosed for the period ending December 31, 2023, related to grant revenue transactions.
Plus Therapeutics entered into a $50 million equity line of credit (purchase agreement) with Lincoln Park Capital Fund, LLC. This arrangement allows the company to sell common stock at a discount to market prices over a 36-month period to fund working capital and repay existing warrant holders.
🚩 Red Flags
- Highly dilutive financing structure (equity line of credit/at-the-market style) which typically puts downward pressure on share price.
- Significant 'Make-Whole Repayment' obligation of $17.3 million, representing a large portion of the potential capital raise.
- The purchase price includes a built-in discount to market prices (97% or 96.5%), which is characteristic of predatory/dilutive financing in micro-caps.
📋 Key Facts
- Entered into a Purchase Agreement and Registration Rights Agreement with Lincoln Park Capital Fund, LLC on June 17, 2025.
- Lincoln Park committed to purchase up to $50 million of common stock over a 36-month period.
- Purchase price for Regular Purchases is 97% of the lower of the current sale price or the 10-day average closing price.
- The company must pay an initial commitment fee of $500,000 (cash/stock) and a potential second $500,000 fee if $25 million in sales are reached.
- Company is obligated to repay approximately $17.3 million to warrant holders via a 'Make-Whole Repayment' using 90% of proceeds from capital raised after July 1, 2025.
Plus Therapeutics entered into a Letter Agreement to restructure significant dilutive securities issued in a March 2025 private placement. The agreement involves the cancellation of Series A Warrants and a massive reduction in the number of shares issuable under Series B Warrants.
🚩 Red Flags
- Extreme dilution risk previously identified (Series B Warrants potentially covering 1.2 billion shares).
- Significant restructuring of debt/equity obligations suggests previous terms were unsustainable or overly predatory.
- Company must use 90% of future capital raised to repay the returned securities, which may severely limit operational runway.
📋 Key Facts
- Cancellation of all outstanding Series A Warrants in full.
- Series B Warrants amended to reduce total issuable shares from over 1.2 billion (potential) to approximately 35.5 million shares.
- Cashless exercise ratio for Series B Warrants reduced from 3:1 to 1:1.
- Purchasers agreed to return 12,241,986 Private Placement Shares and 10,633,650 Pre-Funded Warrant Shares upon Company request.
- Company will repay the returned securities at 115% of their original value using 90% of proceeds from capital raised after July 1, 2025.
- Termination of existing Registration Rights Agreement.
Plus Therapeutics, Inc. received a notice from Nasdaq stating it is in non-compliance with the Minimum Stockholders' Equity Requirement after reporting a deficit of $23.6 million in its Q1 2025 10-Q. The company has been notified of delisting and intends to appeal the decision via a Hearings Panel.
🚩 Red Flags
- Delisting notice from Nasdaq
- Significant stockholders' equity deficit of $23.6 million
- History of compliance issues (previously regained compliance with Rule 5250(c)(1) via filing 10-Q)
- Mandatory Panel Monitor status was previously imposed in March 2025
- Liquidity and financing risks mentioned in forward-looking statements
📋 Key Facts
- Nasdaq issued a letter on June 3, 2025, notifying the Company of non-compliance with Rule 5550(b)(1).
- The Company reported stockholders' equity (deficit) of ($23,641,000) as of March 31, 2025.
- Nasdaq requires a minimum of $2.5 million in stockholders' equity for continued listing.
- The Company must request an appeal to a Hearings Panel by June 10, 2025.
- Trading of PSTV common stock is stayed pending the outcome of the hearing process.
Plus Therapeutics, Inc. reported its financial results for the first quarter ended March 31, 2025, via a press release furnished as an exhibit.
📋 Key Facts
- Reporting period: First quarter ended March 31, 2025
- Filing date: May 30, 2025
- The filing includes results of operations and financial condition updates via Exhibit 99.1.
Plus Therapeutics, Inc. received a notice from Nasdaq regarding non-compliance with listing rules due to a delay in filing its Quarterly Report (Form 10-Q) for the period ended March 31, 2025. The company must submit a compliance plan by July 21, 2025.
🚩 Red Flags
- Delisting notice/Non-compliance with Nasdaq listing rules
- Failure to file timely periodic financial reports (Form 10-Q)
- Potential risk of delisting if compliance plan is not approved or executed within the 180-day window.
📋 Key Facts
- Received Nasdaq notice on May 21, 2025.
- Non-compliance is due to delay in filing Form 10-Q for the period ended March 31, 2025.
- Violation of Nasdaq Listing Rule 5250(c)(1) regarding timely periodic financial reports.
- Deadline to submit a plan to regain compliance: July 21, 2025.
- Potential grace period for delinquent filings expires November 17, 2025.
Plus Therapeutics, Inc. received a notice from Nasdaq stating it is in violation of the minimum bid price requirement after its stock closed below $1.00 for 30 consecutive business days. The company has an initial 180-day compliance period to regain compliance by November 12, 2025.
🚩 Red Flags
- Delisting notice from Nasdaq
- Potential for mandatory reverse stock split to regain compliance
- Persistent low share price (below $1.00)
📋 Key Facts
- Nasdaq notice received on May 16, 2025.
- Violation of Nasdaq Listing Rule 5550(a)(2) due to closing bid price below $1.00 for 30 consecutive business days.
- Initial compliance period expires November 12, 2025.
- To regain compliance, stock must meet or exceed $1.00 for at least 10 consecutive business days before the deadline.
- A second 180-day extension may be available if market value requirements are met and a reverse stock split is utilized to cure the deficiency.
Plus Therapeutics, Inc. stockholders approved several major proposals at a special meeting on May 2, 2025, including authorization for a reverse stock split and a massive increase in authorized common stock. The filing also details significant warrant reset provisions that could lead to substantial share dilution.
🚩 Red Flags
- Reverse stock split authorization (typically used to maintain Nasdaq listing compliance).
- Extreme potential for dilution due to warrant resets and cashless exercise provisions.
- Massive increase in authorized share count (20x increase) which facilitates further dilutive offerings.
📋 Key Facts
- Stockholders approved a reverse stock split with a ratio range of 1-for-25 to 1-for-250, to be implemented within 12 months.
- Authorized common stock increased from 100,000,000 shares to 2,000,000,000 shares.
- Warrant exercise price reset: The exercise price of warrants will reset to the greater of a 10-day VWAP or a floor price of $0.132.
- Series B Warrants include a 'zero exercise price' provision (alternative cashless exercise) which triples the number of shares issuable upon exercise.
- Potential dilution: If Series A warrants hit the floor price and are exercised via cashless method, up to 841,263,490 total shares could be issued from those specific tranches.
Plus Therapeutics, Inc. announced a change in its Board of Directors, appointing Kyle Guse to fill the vacancy created by the resignation of Greg Petersen. Mr. Guse will serve as an independent director and will chair the Audit Committee.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Kyle Guse appointed to the Board of Directors effective April 18, 2025.
- Mr. Guse appointed to the Audit Committee (as Chairman) and Compensation Committee.
- Greg Petersen resigned from the Board; stated resignation was not due to any disagreement with Company operations or practices.
- Kyle Guse previously served as CFO/General Counsel at Atossa Therapeutics, Inc. (Nasdaq-listed biotech).
- Mr. Guse is an inactive CPA and former partner at Baker Botts LLP and McDermott Will & Emery LLP.
Plus Therapeutics, Inc. filed an 8-K to announce its financial results for the fourth quarter and fiscal year ended December 31, 2024.
📋 Key Facts
- Reported financial results for Q4 and FY 2024 on March 27, 2025.
- The filing includes a press release (Exhibit 99.1) detailing recent corporate updates.
- The report was signed by Marc H. Hedrick, M.D., President and CEO.
Plus Therapeutics, Inc. has regained compliance with Nasdaq's minimum stockholders' equity requirement following a private placement. However, the company is now subject to a Mandatory Panel Monitor until March 2026 due to its previous non-compliance.
🚩 Red Flags
- Mandatory Panel Monitor status: Any future deficiency in stockholders' equity before March 2026 will result in an immediate Delist Determination Letter without the ability to submit a compliance plan or receive additional time.
- History of non-compliance with minimum equity requirements.
📋 Key Facts
- Regained compliance with Nasdaq Listing Rule 5550(b)(1) (Minimum Stockholders' Equity Requirement) as of March 7, 2025.
- Compliance was achieved via a Private Placement disclosed on March 4, 2025.
- Funds from the Private Placement are being released from escrow following Nasdaq's confirmation.
- The company is subject to a Mandatory Panel Monitor until March 7, 2026, per Nasdaq Listing Rule 5815(d)(4)(B).
Plus Therapeutics entered into a $15.0 million private placement agreement to issue common stock and warrants to accredited investors, primarily to address Nasdaq minimum stockholders' equity compliance requirements. The deal includes significant warrant coverage (Series A and B) with reset provisions and is contingent upon the company maintaining its Nasdaq listing.
🚩 Red Flags
- Highly dilutive structure: Each share issued comes with two additional warrants (Series A and B).
- Warrant Reset/Anti-dilution: Series A and B warrants contain reset provisions, which can lead to massive further dilution.
- Contingent Closing: The deal is contingent on Nasdaq confirming the company has regained compliance; if not by March 31, 2025, the deal terminates.
- Death Spiral characteristics: The combination of low-priced equity issuance and warrants with reset provisions is a hallmark of 'death spiral' financing.
📋 Key Facts
- Private placement of approximately $15.0 million in gross proceeds expected at closing.
- Issuance of 28,042,140 securities (Common Stock or Prefunded Warrants) plus Series A and B warrants for each share/warrant.
- Combined purchase price is $0.66 per share/prefunded warrant.
- Series A Warrants have an initial exercise price of $1.32 with anti-dilution protection and reset provisions.
- Series B Warrants have an initial exercise price of $1.98 with a cashless exercise option allowing for 3x the number of shares.
- $3.2 million of the issuance is to be used to exchange/cancel outstanding senior convertible promissory notes.
- Funds are held in escrow pending confirmation from Nasdaq that the company has demonstrated compliance with minimum stockholders' equity requirements.
Plus Therapeutics entered into a $6.55 million financing involving secured convertible promissory notes and warrants with existing accredited investors. The deal includes significant anti-dilution protections, mandatory conversion triggers upon a qualified financing, and requires shareholder approval for certain price adjustments.
🚩 Red Flags
- High-interest secured debt (10% per annum) backed by substantially all company assets.
- Significant potential dilution via convertible notes and warrants at $1.12/share.
- Mandatory conversion provisions that could force equity issuance upon a successful financing.
- Requirement for repeated stockholder meetings to obtain approvals for price adjustments.
📋 Key Facts
- Issued $3,362,251 in new 'Funding Notes' maturing February 13, 2026, at 10% interest.
- Issued $3,188,922 in 'Exchange Notes' to cancel existing Series A Warrants.
- Warrants issued for 3,002,009 shares of common stock at an exercise price of $1.12 per share.
- The notes are secured by a pledge of substantially all assets of the Company and its subsidiary, CNSide Diagnostics, LLC.
- Mandatory conversion trigger: If a 'Qualified Financing' of $\ge$ $10M occurs before March 31, 2025, notes may be mandatorily converted into new securities.
- The company must seek stockholder approval by May 30, 2025, for various anti-dilution and warrant adjustments.
Plus Therapeutics, Inc. filed an 8-K to announce its financial results for the third quarter ended September 30, 2024. The filing serves as a formal notification that quarterly earnings data and corporate updates have been released via press release.
📋 Key Facts
- Reported financial results for the third quarter ended September 30, 2024.
- Filing date: November 14, 2024.
- The report includes a press release (Exhibit 99.1) containing recent corporate updates.
Plus Therapeutics, Inc. received a decision from a Nasdaq Hearings Panel granting the company until March 4, 2025, to regain compliance with the Minimum Stockholders' Equity Requirement. This follows a previous notice of non-compliance and an appeal by the company.
🚩 Red Flags
- Delisting risk: The company is currently in non-compliance with Nasdaq listing rules.
- Capitalization issues: Failure to maintain $2.5 million in stockholders' equity indicates significant financial distress or dilution concerns.
- Uncertainty of compliance: Management explicitly states there can be no assurance that the company will demonstrate compliance by the deadline.
📋 Key Facts
- The Company failed to meet Nasdaq Listing Rule 5550(b)(1) regarding the $2.5 million minimum stockholders' equity requirement.
- A Nasdaq Hearings Panel held a hearing on October 22, 2024.
- On October 30, 2024, the Panel granted a compliance period until March 4, 2025.
- Compliance is required to avoid delisting from the Nasdaq Capital Market.
Plus Therapeutics, Inc. received notice from Nasdaq that it has failed to regain compliance with the minimum stockholders' equity requirement. The company intends to appeal the determination to stay any suspension or delisting of its common stock.
🚩 Red Flags
- Delisting notice from Nasdaq due to failure to meet minimum stockholders' equity requirements.
- Negative stockholders' equity of ($1,348,000) as of year-end 2023.
- Failure to satisfy alternative listing standards (market value or net income).
- Risk of trading suspension if the appeal is unsuccessful.
📋 Key Facts
- Nasdaq notified the Company on September 5, 2024, that it has not regained compliance with Nasdaq Listing Rule 5550(b)(1).
- The company failed to meet the $2.5 million minimum stockholders' equity requirement.
- As of December 31, 2023, the Company reported negative stockholders' equity of ($1,348,000).
- The Company intends to timely appeal the determination to a Nasdaq Hearings Panel to trigger an automatic stay of delisting.
Plus Therapeutics, Inc. held its 2024 Annual Meeting of Stockholders on August 15, 2024. The meeting resulted in the election of six directors and the approval of several key shareholder proposals including auditor ratification and compensation plans.
📋 Key Facts
- Annual Meeting held on August 15, 2024.
- Six directors were elected to terms expiring in 2025: Howard Clowes, An van Es-Johansson, M.D., Richard J. Hawkins, Marc H. Hedrick, M.D., Robert Lenk, Ph.D., and Greg Petersen.
- BDO USA, P.C. was ratified as the independent registered public accounting firm for fiscal year 2024.
- Shareholders approved an advisory vote on executive compensation (Say-on-Pay).
- Shareholders approved the fourth amendment and restatement of the Company’s 2020 Stock Incentive Plan.
- Quorum was established with 2,484,122 shares represented out of 5,704,219 total shares outstanding.
Plus Therapeutics, Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2024. The filing serves as a formal announcement of quarterly earnings and recent corporate updates.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2024.
- Report date: August 14, 2024.
- The company included a press release (Exhibit 99.1) detailing financial results and corporate updates.
Plus Therapeutics, Inc. announced the resignation of its Chief Medical Officer, Dr. Norman LaFrance, effective June 12, 2024.
🚩 Red Flags
- Departure of a key executive (Chief Medical Officer) in a clinical-stage biotech company can impact R&D momentum or regulatory strategy.
📋 Key Facts
- Dr. Norman LaFrance resigned from his position as Chief Medical Officer.
- The resignation is scheduled to become effective on June 12, 2024.
- The announcement was made via an 8-K filing dated June 7, 2024.
Plus Therapeutics, Inc. drew $3.3 million from its existing Pershing Credit Facility to fully repay an outstanding Oxford Term Loan as of May 31, 2024. This move effectively refinances the company's debt by moving it into a margin loan facility secured by marketable securities.
🚩 Red Flags
- Debt is 'due on demand', creating significant liquidity risk if collateral value drops.
- Refinancing existing debt with a margin loan (secured by marketable securities) suggests limited access to traditional non-recourse financing.
- The facility requires the company to maintain specific collateral levels; a market downturn could trigger a requirement to deposit more cash or securities.
📋 Key Facts
- Drew $3.3 million from the Pershing Credit Facility on May 31, 2024.
- Used proceeds to fully repay the Oxford Term Loan (principal and interest) on June 3, 2024.
- The Pershing Credit Facility is a margin loan secured by collateralized marketable securities held with Pershing LLC.
- Borrowing terms: Interest rate is FOMC target rate + 1.75% spread + 0.5% fees (subject to caps/floors).
- The facility allows drawing up to 91.5% of the value of the collateralized marketable securities.
Plus Therapeutics, Inc. announced the date and logistics for its 2024 Annual Meeting of Stockholders. The meeting is scheduled to be held virtually on August 15, 2024.
📋 Key Facts
- Annual Meeting Date: Thursday, August 15, 2024, at 9:00 a.m. ET.
- Meeting Format: Virtual via remote communication.
- Record Date for Voting: June 25, 2024 (close of business).
- Deadline for Shareholder Proposals/Nominations: May 30, 2024, at 5:00 p.m. ET.
Plus Therapeutics, Inc. filed an 8-K to report its financial results for the quarter ended March 31, 2024 and provide other corporate updates.
📋 Key Facts
- Reported financial results for the fiscal quarter ended March 31, 2024.
- Filing includes a press release (Exhibit 99.1) detailing recent corporate updates.
- The report was signed by CEO Marc H. Hedrick, M.D. on May 15, 2024.
Plus Therapeutics, Inc. entered into a securities purchase agreement and an amendment to raise approximately $7.25 million in gross proceeds through the issuance of common stock and warrants. The deal includes significant registration rights obligations with liquidated damages provisions.
🚩 Red Flags
- Significant dilution: The issuance of over 3.5 million shares plus warrants will result in substantial shareholder dilution.
- Liquidated damages clause: The company is liable for liquidated damages (1% per purchaser, capped at 12%) if it fails to file a registration statement within 30 days or if the registration statement is not declared effective within 90 days.
- Warrant overhang: The potential issuance of warrants could lead to further dilution upon exercise.
📋 Key Facts
- Initial subscription for $6.5 million on May 5, 2024; amended on May 8, 2024 to increase total proceeds to approximately $7.25 million.
- Issuance of 3,591,532 securities (Common Stock or Pre-Funded Warrants) accompanied by Series A and Series B warrants.
- Series A warrants have an exercise price of $1.772; Series B warrants have an exercise price of $1.908.
- Company Insiders participated in the initial subscription with a total purchase of $98,500 at $2.04 per share/warrant package.
- The company expects potential future warrant cash exercise proceeds of up to $12.0 million, bringing total gross proceeds to ~$19.25 million.
Plus Therapeutics, Inc. received a notice from Nasdaq stating it is non-compliant with the minimum stockholders' equity requirement of $2.5 million. As of December 31, 2023, the company reported negative stockholders' equity of ($1,348,000).
🚩 Red Flags
- Delisting notice from Nasdaq
- Negative stockholders' equity (deficiency of approximately $3.85M to meet the Equity Standard)
- Failure to meet Alternative Standards (Market Value or Net Income)
📋 Key Facts
- Received Nasdaq notice on March 8, 2024.
- Non-compliance with Nasdaq Listing Rule 5550(b)(1) regarding the $2.5 million Equity Standard.
- Stockholders' equity was reported as ($1,348,000) as of December 31, 2023.
- Company must submit a Compliance Plan by April 22, 2024.
- Potential extension to regain compliance is available until September 4, 2024.
Plus Therapeutics, Inc. filed an 8-K to disclose a presentation made by CEO Marc Hedrick at a JonesResearch webcast on March 12, 2024. The filing includes investor slides as Exhibit 99.1.
📋 Key Facts
- CEO Marc Hedrick presented at a JonesResearch webcast on March 12, 2024.
- The presentation was made available via the Company's website under the 'For Investors' tab.
- Investor slides from the presentation are attached as Exhibit 99.1.
Plus Therapeutics, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2023. The filing serves as a formal announcement of quarterly earnings and corporate updates via an attached press release.
📋 Key Facts
- Reporting period: Fourth quarter and full year ended December 31, 2023.
- Filing date: March 5, 2024.
- The report includes financial results and other recent corporate updates via Exhibit 99.1.